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for diagnosis and treatment. Since January 1995, we have
preferred to use a medical approach for the initial manage-
ment of MVT, with anticoagulation therapy alone and
close follow-up. The aim of this study was to analyze the
outcome of patients admitted in our surgical unit for MVT
in a 12-year period. The results obtained in each of the two
groups in which either surgical or medical therapy was pri-
marily performed during this period were assessed to deter-
mine the best management of this uncommon disease.
MATERIALS AND METHODS
We retrospectively reviewed the clinical course of 26
patients treated for acute MVT between January 1, 1987,
and December 31, 1999. This group represented 9.2% of
the 281 patients treated for mesenteric ischemia, whatever
its cause, during the same period in our department. The
department is a primary and secondary care surgical
department. No patient with acute MVT (as defined) was
excluded from the current study. We restricted the diag-
nosis of acute MVT to patients with symptoms of less than
4 weeks’ duration.4 Patients who incidentally were found
to have MVT by means of abdominal computed tomogra-
phy (CT) scans that had been obtained for other reasons
were excluded. Primary MVT was defined as thrombosis
of a mesenteric vein that was not associated with any other
disease or etiologic factor. The term secondary MVT was
used for patients with any condition known to predispose
them to MVT. These conditions include earlier abdominal
surgery, blunt abdominal trauma, oral contraceptive use,
Mesenteric venous thrombosis (MVT) is a rare but
potentially lethal form of mesenteric ischemia. MVT must
be distinguished from arterial and nonocclusive types of
mesenteric ischemia, and accounts for 5% to 15% of all cases
of mesenteric ischemia. Patients may have evocative signs,
such as abdominal pain, nausea, or vomiting. However, a
clinical diagnosis is often difficult because abdominal symp-
toms are nonspecific.1 Primary MVT accounted for 25% to
55% of cases in early studies, but recent reports show a
decline in primary MVT because of improvements in the
diagnosis of hypercoagulable states.2 Advances in new
imaging techniques also have enabled early recognition of
this disease without or before laparotomy.3-5 There is no
consensus about initial treatment in the management of
MVT. Some authors have proposed an aggressive surgical
approach,6 whereas others have advocated medical therapy.7
Before January 1995, our department policy was to
perform an operation first in patients with suspected MVT
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Objective: Initial treatment in the management of acute mesenteric vein thrombosis (MVT) is controversial. Some
authors have proposed a surgical approach, whereas others have advocated medical therapy (anticoagulation). In this
study, we analyzed and compared the results obtained with surgical and medical treatment to determine the best initial
management for this disease.
Methods: We retrospectively reviewed the records of patients treated for MVT in a secondary care surgical department
from January 1987 to December 1999. Before January 1995, our departmental policy was to perform surgery in
patients with suspected MVT. Since January 1995, we have preferred a medical approach when achievable. Each patient
in this study was assessed for diagnosis, initial management (laparotomy or anticoagulation), morbidity, mortality,
duration of hospitalization, the need for secondary operation, portal hypertension, and survival rates.
Results: Twenty-six patients were treated, 14 before January 1995 (group 1) and 12 since January 1995 (group 2).
Morbidity, mortality, secondary operation, portal hypertension, and 2-year survival rates were 34.6%, 19.2%, 15.3%,
19.2%, and 76.9%, respectively. No statistical difference was observed between the two groups. The mean duration of hos-
pitalization was 51.6 days in group 1 and 23.2 days in group 2 (P < .05). Among the 12 patients treated by means of
laparotomy with bowel resection, 10 patients (83%) had mucosal necrosis without transmural necrosis at pathologic study.
Conclusion: Nonoperative management for acute MVT is feasible when the initial diagnosis with a computed tomogra-
phy scan is certain and when the bowel infarction has not led to transmural necrosis and bowel perforation. The mor-
bidity, mortality, and survival rates are similar in cases of surgical and nonoperative management. The length of hospital
stay is shorter when patients are treated with a nonoperative approach. A nonoperative approach, when indicated,
avoids the resection of macroscopically infarcted small bowel (without transmural necrosis) in cases that are potentially
reversible with anticoagulation alone. (J Vasc Surg 2001;34:673-9.)
inflammation, portal hypertension, or hypercoagulable
states.5
The diagnosis of acute MVT was established either if
there was a positive CT scan result or when the patient
underwent a laparotomy. A CT scan was considered to be
positive for MVT when a thrombus in the superior mesen-
teric vein or an abnormal thickening of ischemic bowel
wall with streaky mesentery was demonstrated.4,5
Laparotomy permitted diagnosis of MVT either by means
of macroscopic findings after dissection of the superior
mesenteric vein (thrombosis) or by means of macroscopic
and microscopic pathologic studies of resected small
bowel segments. Hematoxylin-eosin–stained sections of
each specimen of resected small bowel were reviewed by
one of the authors (L.A.) to assess the extent of intramural
or transmural bowel necrosis.
Our departmental policy concerning the treatment of
patients with clinical suspicion of MVT changed during
the period of this study. Before January 1995, patients
with the clinical suspicion of MVT underwent an opera-
tion as a means of confirming diagnosis and performing
treatment (group 1). During this period, when a CT scan
was performed at admission and was used as a means of
confirming the diagnosis of MVT without peritoneal signs
(guarding), patients were treated with anticoagulation
alone. Eighty-six percent of the patients in this group were
treated surgically. After January 1995, all patients under-
went a CT scan at the time of their admission to the hos-
pital (group 2). Patients who had a confirmed diagnosis of
MVT by means of the initial CT scan and did not have
peritoneal signs (guarding) were treated with anticoagula-
tion alone. Ninety-two percent of the patients in this
group were treated with anticoagulation.
In all patients, treatment at admission included intra-
venous fluid administration and prophylactic antibiotic
therapy. Intravenous heparin was given at the time of diag-
nosis when we decided to use nonsurgical management.
Systemic administration of heparin was guided by the acti-
vated partial thromboplastin time (APTT), and a mini-
mum of two times the normal APTT value was preferred.
Close clinical and hemodynamic follow-up of these
patients was undertaken in an intensive care unit. When
surgical management was chosen, a laparotomy was per-
formed within 6 hours after the patient’s admission. In
these cases, intravenous heparin was given immediately at
the end of the operation, with the same parameters used
in management with anticoagulation alone.5 After initial
treatment (medical or surgical), the systemic administra-
tion of heparin was followed in all cases by anti–vitamin K
therapy. The presence of coagulation abnormalities was
investigated at 3 months. When present, anti–vitamin K
therapy was maintained permanently. If no coagulation
abnormality was found, anti–vitamin K therapy was main-
tained for 6 months. The duration of hospitalization was
evaluated for both the initial length of hospital stay and
the total number of hospitalizations related to MVT
(stoma closure, incisional hernia, reoperation). Sepsis was
defined as any septic event leading to death. Morbidity,
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Table I. Patient characteristics
All patients Group 1 Group 2
No. 26 14 12
Age (y) 55.0 ± 3.6 53.5 ± 4.7 56.7 ± 5.9
Sex
Men 18 12 6
Women 8 2 6
ASA score > 3 (%) 15 7 25
ASA, American Society of Anesthesiologists.
Table II. Conditions associated with MVT
All patients Group 1 Group 2
Primary (%) 9 (34.6) 8 (57.1) 1 (8.3)
Secondary (%) 17 (65.4) 6 (42.9) 11 (91.7)*
Earlier abdominal surgery 5 1 4
Leiden factor V 3 2 1
Deep venous thrombosis 2 — 2
Oral contraceptive use 2 1 1
Alcohol abuse 1 1 —
Malignant tumor 1 — 1
Anticardiolipin antibodies 1 — 1
Protein S deficiency 1 1 —
Protien C deficiency 1 — 1
*P < .05.
mortality, the need for secondary operations, portal hyper-
tension, and survival rates were assessed.
Statistical analysis was performed with Statview soft-
ware (Abacus Concepts, Berkeley, Calif). The Yates cor-
rected χ2 test was used as a means of evaluating differences
in categoric variables, and the Mann-Whitney U test was
used for continuous variables. Kaplan-Meier estimates
were used as a means of assessing survival, and the log-
rank test was used as a means of testing for differences in
survival between groups. All values were expressed as a
mean ± SE. Statistical significance was accepted when the
P value was less than .05.
RESULTS
Acute mesenteric vein thrombosis was diagnosed in 18
men and eight women. Their mean age was 55 ± 3.6 years.
Fourteen patients (54%) were treated in the first period
(group 1), and 12 patients (46%) were treated in the last
period (group 2). The mean age, the sex ratio, and the
American Society of Anesthesiologists score at admission
were similar in the two groups (Table I). Seventeen
patients (65.4%) were found to have conditions currently
known to predispose them to MVT. Nine patients (34.6%)
were considered to have primary MVT. Predisposing con-
ditions associated with secondary mesenteric venous
thrombosis were more frequently found (P < .05) in
group 2 (Table II).
The most common presenting symptom was abdomi-
nal pain (100%). Other symptoms included vomiting
(27%), diarrhea (23%), and constipation (23%)(Table III).
The mean duration of presenting symptoms before admis-
sion was 4.7 ± 0.8 days. Nineteen patients (73%) had dif-
fuse abdominal pain. When pain was localized, it was
located in the upper quadrants in four patients and in the
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 4 Brunaud et al 675
lower quadrants in three patients. Physical findings at
admission were abdominal distention in nine patients
(34.6%) and peritoneal signs in eight patients (30.8%).
The mean temperature of patients at admission was 37.7 ±
0.1°C. The mean white blood cell count and amylase level
were 18.1 ± 1.3 109/L and 61.4 ± 9.3 IU/L, respectively.
Systolic hypotension (defined as < 90 mm Hg) at admis-
sion was present in five patients. There was no difference
in these parameters between the two groups.
A CT scan was performed at admission in 18 patients
(69.2%), including six patients(42.8%) from group 1 and
12 patients (100%) from group 2 (P < .01). A thrombus
in the superior mesenteric vein (SMV) was demonstrated
by means of a CT scan in 16 patients (88.9%). Thrombosis
extended to the portal vein in 10 patients (62.5%) and to
the splenic vein in one patient. Bowel wall thickening and
peritoneal effusion were found in 16 patients (88.9%).
There was no difference in the incidence of these findings
between the two groups (Table IV). In group 1, the diag-
nosis of MVT was established by means of CT scanning in
five patients (35.7%) and by means of laparotomy in nine
patients (64.3%). In group 2, the diagnosis was established
by means of CT scanning in 11 patients (91.6%) and by
means of laparotomy in one patient (8.4%).
The initial management in this study consisted of anti-
coagulation in 13 patients (50%) and laparotomy in 13
patients (50%). In group 1, 12 patients underwent laparo-
tomy. Of these, four patients underwent operations after a
CT scan (3 with peritoneal signs and 1 with an uncertain
diagnosis despite the CT scan). Two patients (14%) in
group 1 were treated with anticoagulation alone and thus
received treatment that was identical to that of most
patients in group 2. In group 2, 11 patients were treated
with anticoagulation alone, and one patient was treated
Table III. Symptoms and findings at admission
All patients (%) Group 1 (%) Group 2 (%)
Abdominal pain 26 (100) 14 (100) 12 (100)
Diffuse abdominal pain 19 (73) 10 (71.4) 9 (75)
Localized abdominal pain 7 (27) 4 (28.6) 3 (25)
Vomiting 7 (27) 4 (28.6) 3 (25)
Diarrhea 6 (23) 3 (21.4) 3 (25)
Constipation 6 (23) 2 (14.3) 4 (33.3)
Symptoms duration (d) 4.7 ± 0.8 4.8 ± 1.2 4.4 ± 0.8
Symptoms duration ≤ 48 h 9 (34.6) 5 (35.7) 4 (33.3)
Peritoneal signs 8 (30.8) 5 (35.7) 3 (25)
Abdominal tenderness 4 (15) 1 (7) 3 (25)
Guarding 4 (15) 4 (28.6) 0 (
Abdominal distension 9 (34.6) 6 (42.9) 3 (25)
Blood (digital rectal examination) 8 (30.8) 4 (28.6) 4 (33.3)
Temperature (°C) 37.7 ± 0.1 37.7 ± 0.8 37.8 ± 0.3
Temperature ≥ 38°C 11 (42.3) 6 (42.9) 5 (41.7)
Pulse rate (bpm) 104 ± 3 109 ± 5 98 ± 4
WBC (109/L) 18.1 ± 1.3 19.4 ± 6.6 16.7 ± 6.9
Amylases (IU/L)* 61.4 ± 9.3 81.5 ± 15.8 41.2 ± 5.6
Hypotension (< 90 mm Hg) 5 (19.2) 2 (14.3) 3 (25)
*Reference range < 98 IU/L.
WBC, White blood cell count.
surgically (P < .001). Bowel wall thickening was shown by
means of a preoperative CT scan in this patient, but the
diagnosis of MVT was not confirmed.
Of the 13 patients who underwent operations, one
patient in group 1 had peritoneal signs (guarding) and was
found to have an extensive infarction of the small bowel
and the right colon at laparotomy. In this patient, the
SMV was exposed to confirm its thrombosis, but no bowel
resection was performed. This patient died 6 hours post-
operatively. In the other 12 patients, macroscopic involve-
ment of bowel segments, featuring dark red coloration
with marked wall thickening, was revealed by means of the
surgical exploration. An infarcted small bowel lesion with-
out macroscopic perforation was found in 10 patients
(83%), and sealed perforations of infarcted small bowel
without generalized peritonitis were found in two patients
(17%). All macroscopic bowel lesions were resected, and
no thrombectomy or thrombolytic therapy was per-
formed. The mean length of resected bowel was 100 ± 18
cm. Immediate bowel anastomosis was performed in six
cases, and ileostomy was performed in another six cases.
Histologic features of ischemia, including submucosal
congestion, hemorrhage, and edema of the intestinal wall,
were observed in all 12 patients. Early epithelial damage
restricted to the mucosa without ischemic involvement of
the entire thickness of the bowel wall was observed in 10
patients (83%). Complete coagulative necrosis (transmural
necrosis) of the bowel wall was found in two patients
(17%). Peritoneal signs (abdominal tenderness in two
patients and guarding in one patient) were present before
laparotomy in three (30%) of the patients whose micro-
scopic features showed only mucosal necrosis. Both
patients with transmural necrosis had peritoneal signs
(guarding) before laparotomy.
In-hospital morbidity occurred in 34.6% of patients,
with no significant difference between the two groups
(Table V). Cavernous transformation of the portal vein
(CTPV) was observed in five patients (19.2%). This com-
plication occurred in two patients in group 1 who were
treated surgically, and in three patients in group 2 who
were treated with anticoagulation alone. Three of these
patients had no symptoms, whereas two patients had
episodes of variceal bleeding that were documented by
means of endoscopy.
A secondary operation after initial treatment was
needed in four patients (15.3%; Table V). One patient in
group 1 had chronic intestinal obstruction 10 weeks after
initial treatment with anticoagulation. This patient under-
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Table V. Morbidity, mortality, and outcome
All patients (%) Group 1 (%) Group 2 (%)
Morbidity 9 (34.6) 7 (50) 2 (16.6)
Pneumonia 5 (19.2) 3 (21.4) 2 (16.6)
Wound infection 3 (11.5) 3 (21.4) 0 (
Renal failure 2 (7.6) 2 (14.2) 0 (
Sepsis 2 (7.6) 1 (7.1) 1 (8.3)
Short bowel syndrome 1 (3.8) 1 (7.1) 0 (
Cavernous transformation of the portal vein 5 (19.2) 2 (14.3) 3 (25)
Secondary operation 4 (15.3) 1 (7.1) 3 (25)
Bowel perforation 2 ( — 2 (16.6)
Bowel stricture 1 ( 1 (7.1) —
Portal hypertension 1 ( — 1 (8.3)
Mortality (≤ 24 h) 3 (11.5) 1 (7.1) 2 (16.6)
Mortality (≤ 30 d) 5 (19.2) 2 (14.3) 3 (25)
Mean follow-up (mo) 51.3 ± 9.1 74.2 ± 13.8 24.6 ± 5.3
Two-year survival (%) 76.9 78.6 75 (
Table IV. CT scan findings
All patients (%) Group 1 (%) Group 2 (%)
CT scan 18 6 (42.8) 12 (100)*
MVT diagnosis 16 (88.9) 5 (83.3) 11 (91.6)
Thrombus SMV 16 (88.9) 5 (83.3) 11 (91.6)
Wall thickening 16 (88.9) 6 (100) 10 (83.3)
Peritoneal effusion 16 (88.9) 6 (100) 10 (83.3)
Streaky mesentery 12 (66.6) 4 (67) 8 (67)
Thrombus portal vein 10 (62.5) 3 (60) 7 (63.6)
Thrombus splenic vein 1 (6) – 1 (9)
*P < .01.
went surgery for intestinal stricture caused by MVT, and
18 cm of jejunum were resected with immediate reanasto-
mosis. Two patients in group 2 who did not initially have
peritoneal signs underwent operations for secondary small
bowel perforations. Both patients had peritoneal signs that
occurred 24 days and 25 days after their initial treatment
with anticoagulation. Resections of 20 cm and 25 cm of
small bowel were performed with immediate anastomosis
in one patient and with ileostomy in the other. The third
patient in group 2 returned with extrahepatic portal
hypertension and cavernous transformation of the portal
vein 10 months after the initial treatment with anticoagu-
lation. Because the treatment of recurrent bleeding gas-
troesophageal varices with endoscopic sclerotherapy was
unsuccessful, this patient underwent esophagogastric
devascularization and esophageal transection.
The mean duration of hospitalization for initial treat-
ment was 51.6 ± 14.9 days for patients in group 1 and
23.2 ± 8.4 days for patients in group 2 (P < .05). The total
hospital stay, including readmissions, was 62.4 ± 16.3 days
for patients in group 1 and 28.5 ± 11 days for patients in
group 2 (P < .025). The 24-hour mortality rate was
11.5%; one patient in group 1 and two patients in group
2 died of MVT. The 30-day mortality rate was 19.2%; two
patients died because of comorbid conditions (pneumonia
with sepsis) at day 13 in group 2 and at day 28 in group 1
(Table V). The mean follow-up period was 51.3 ± 9.1
months. One patient in group 1 died of a comorbid con-
dition at 6 months (pulmonary edema). The overall 2-year
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survival was 76.9%, and no difference (P < .8) was found
between the two groups (Figure).
Eight of the 10 patients who had thrombus extension
into the portal vein at admission had complications: sec-
ondary CTPV developed in 5 patients, 2 patients had sec-
ondary small bowel perforations, and 1 patient had a
secondary intestinal stricture (Table V). Restoration of
venous flow without thrombus in the SMV was revealed
by means of CT scans in five patients with CTPV, but not
in the two patients with secondary small bowel perfora-
tions or in the patient with secondary intestinal stricture.
DISCUSSION
Acute MVT is defined as a thrombus of the mesenteric
vein with bowel infarction, regardless of its severity.4,8
This study suggests first, that nonoperative management
of acute MVT is feasible when the diagnosis made by
means of the initial CT scan is certain and when bowel
infarction has not led to transmural necrosis and bowel
perforation. Second, initial surgical and nonoperative
approaches are similar in morbidity, mortality, and survival
rates. Third, the hospital stay is shorter when patients are
treated nonoperatively. Finally, a nonoperative approach,
when achievable, avoids the resection of macroscopically
infarcted small bowel without transmural necrosis, which
potentially is reversible with anticoagulation alone.
In a review of the literature from 1911 to 1984, Abdu
et al8 showed that the use of anticoagulants as an adjunct
to bowel resection significantly decreases the mortality
Kaplan-Meier estimates of 2-year survival for patients in group 1 and group 2. There was no difference in
short-term survival between the 2 groups (log-rank test).
rate (22% vs 59%) and improves the survival of patients
(77% vs 65%). The results of surgery associated with anti-
coagulation are similar to those in group 1 in our study.
Currently, the consensus for MVT management is that
patients should receive anticoagulants once the diagnosis
of MVT is established either by means of a diagnostic test
or intraoperatively.1,9,10 Recently, nonoperative treatment
has been proposed in patients with MVT.4,7,11-13 We
changed our preferred treatment from surgical to nonop-
erative management in consideration of the favorable out-
come with anticoagulation alone in two patients in group
1. Our study confirms that nonoperative management is
feasible, but only when the diagnosis of MVT is confirmed
with certainty by means of noninvasive abdominal imaging
at admission. Currently, this can be established by means
of ultrasound scanning, CT scanning, or magnetic reso-
nance imaging.5 Rhee et al4 showed that CT scanning was
the most sensitive tool for detecting acute MVT.
Currently, high-quality abdominal CT scans are used as a
means of detecting MVT in more than 90% of
cases.5,12,14,15 This is substantiated by the current study.
The second criterion for nonoperative management is
the absence of transmural bowel necrosis at admission.
Evaluation of the actual severity of bowel ischemia at
admission is difficult. When peritoneal signs initially are
present, an immediate operation is probably indicated.4,5
We agree with Chen et al3 that guarding indicates the need
for laparotomy because of the risk of bowel perforation as
a consequence of transmural infarction of the intestine.
However, we encountered mucosal necrosis without trans-
mural necrosis or bowel perforation in three patients with
peritoneal signs (abdominal tenderness in two patients and
guarding in one patient). This suggests that peritoneal
signs may not strictly correlate to the severity of bowel
ischemia, thus accounting for the difficulty in establishing
a clinical diagnosis of intestinal infarction.16 Greater accu-
racy in the evaluation of bowel ischemia may be attainable
in the future with gastric intramural pH measurement17 or
with the evaluation of bowel wall thickening by means of
contrast-enhanced CT scanning.15 These examinations
may help the surgeon decide more accurately when non-
operative management is appropriate. Overall, features
allowing nonoperative management have been found in
approximately 36% of the patients who have been reported
in the literature since 1990.4,9,12,18-21 In our study (group
2), this proportion increased to 80% of patients when CT
scans were rapidly performed at admission.
In-hospital complications occurred in 55% of the
patients in the Mayo series.4 In the recent literature, mor-
tality rates have ranged from 29% to 38%4,6,19,20 for surgi-
cal treatment and from 13% to 19%9,12 for nonoperative
management, with 1-year survival of 61% to 77%4,8 and
56%,4 respectively. Because the morbidity, mortality, and
survival rates in our series are consistent with earlier
reports, we think that our patients did not represent a
favorable selection bias and that our conclusions are valid.
Furthermore, patients in group 2 cannot be considered as
having MVT that is more susceptible to cure with antico-
agulants, because the incidence of hypercoagulable states
was similar in both of our treatment groups.
Bowel infarction without transmural necrosis is poten-
tially reversible with anticoagulation.12 This has been
shown by means of the favorable outcome of postopera-
tive anticoagulation in patients with infarction of the
entire small bowel at laparotomy, precluding any bowel
resection.22 When surgical management is routinely used,
the surgeon usually excises all affected bowel at laparo-
tomy because of the impressive macroscopic bowel
appearance that is caused by acute MVT.3,5,7 In our series
(group 1), this strategy led to bowel resection for infarc-
tion without transmural necrosis of about 100-cm length
in 82% of patients who underwent resection. When non-
operative management is achievable, this major bowel
resection is avoided.11,12
Our experience with patients who have peritoneal
signs without transmural bowel necrosis indicates that
peritoneal signs may not strictly correlate with the severity
of ischemia. Even if clinical presentation is relevant in
determining which patients can be observed versus those
patients who require surgery, this criterion should not be
the only one evaluated at admission. New criteria, such as
bowel wall thickness and bowel wall enhancement on the
arterial phase of a CT scan, need further evaluation. Even
with anticoagulation, MVT can cause arteriolar spasm
leading to transmural infarction.3,7,8 This complication
occurs in about 18% of patients who are treated nonoper-
atively.12 The two patients in whom secondary bowel per-
foration developed in our series had no peritoneal signs at
admission. Therefore, clinical findings are not an accurate
means of predicting which patients will have a secondary
bowel perforation that requires a subsequent operation.9
Close follow-up of these patients is mandatory to establish
the diagnosis of secondary bowel perforation.7,12
Secondary intestinal stricture as a consequence of intesti-
nal ischemia has been described in case reports,21,23 but
this complication has occurred in less than 10% of patients
receiving nonoperative treatment. Like other authors, we
have found that even when a secondary bowel resection is
necessary for delayed perforation or stricture, it can fre-
quently be of limited length.12,24
Extrahepatic portal hypertension occurs in 25% of
patients with acute MVT.12 We have demonstrated that
this complication was not specific to patients who were
treated nonoperatively. Moreover, thrombus extension
into the portal vein should be evaluated by means of CT
scanning at admission. When present, it justifies close
monitoring, because it increases the risk of CTPV and sec-
ondary bowel perforation or stricture. Thrombolytic ther-
apy, administered either peripherally or locally, has been
reported.3,25-27 No patient in these reports had CTPV,
which suggests that this therapy might be more effective
than systemic anticoagulants. Because the experience is
limited, however, the role of this therapeutic option
requires further evaluation. Controlled trials will be neces-
sary as a means of prospectively assessing thrombolytic
therapy and nonoperative management.
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In summary, our experience with surgical and nonop-
erative initial treatment of MVT suggests that nonopera-
tive management for acute MVT is feasible when the
initial diagnosis made by means of CT scan is certain and
when bowel infarction has not led to transmural necrosis
and bowel perforation. When a nonoperative approach is
possible, it avoids resection of macroscopically infarcted
small bowel without transmural necrosis in cases that are
potentially reversible with anticoagulation alone. In addi-
tion, the length of hospital stay is shorter. Initial surgical
management and nonoperative approaches are similar in
morbidity, mortality, and survival rates. Because complica-
tions, such as bowel stenosis or perforation, can occur in
patients who are treated nonoperatively, close follow-up
must be performed.
We thank B. Charra for his technical assistance.
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